China: Qiming Venture joins $55m Series B round of Connect Biopharma

China: Qiming Venture joins $55m Series B round of Connect Biopharma

Visual from Therapure Biopharma's website.

Chinese venture capital firm Qiming Venture Partners has participated in the $55-million Series B round of Connect Biopharmaceuticals, a clinical-stage company focused on discovery and development of immune modulators for the treatment of auto-immune diseases.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter